JP2023528435A5 - - Google Patents

Info

Publication number
JP2023528435A5
JP2023528435A5 JP2022574357A JP2022574357A JP2023528435A5 JP 2023528435 A5 JP2023528435 A5 JP 2023528435A5 JP 2022574357 A JP2022574357 A JP 2022574357A JP 2022574357 A JP2022574357 A JP 2022574357A JP 2023528435 A5 JP2023528435 A5 JP 2023528435A5
Authority
JP
Japan
Application number
JP2022574357A
Other languages
Japanese (ja)
Other versions
JPWO2021247800A5 (https=
JP2023528435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035603 external-priority patent/WO2021247800A2/en
Publication of JP2023528435A publication Critical patent/JP2023528435A/ja
Publication of JP2023528435A5 publication Critical patent/JP2023528435A5/ja
Publication of JPWO2021247800A5 publication Critical patent/JPWO2021247800A5/ja
Pending legal-status Critical Current

Links

JP2022574357A 2020-06-03 2021-06-03 遺伝子転写物のモジュレーターを使用する神経学的疾患の処置 Pending JP2023528435A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063033926P 2020-06-03 2020-06-03
US63/033,926 2020-06-03
US202063119717P 2020-12-01 2020-12-01
US63/119,717 2020-12-01
PCT/US2021/035603 WO2021247800A2 (en) 2020-06-03 2021-06-03 Treatment of neurological diseases using modulators of gene transcripts

Publications (3)

Publication Number Publication Date
JP2023528435A JP2023528435A (ja) 2023-07-04
JP2023528435A5 true JP2023528435A5 (https=) 2024-06-10
JPWO2021247800A5 JPWO2021247800A5 (https=) 2024-06-10

Family

ID=78831722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574357A Pending JP2023528435A (ja) 2020-06-03 2021-06-03 遺伝子転写物のモジュレーターを使用する神経学的疾患の処置

Country Status (8)

Country Link
US (1) US20230235332A1 (https=)
EP (1) EP4162051A4 (https=)
JP (1) JP2023528435A (https=)
KR (1) KR20230043819A (https=)
AU (1) AU2021284360A1 (https=)
CA (1) CA3185488A1 (https=)
IL (1) IL298647A (https=)
WO (1) WO2021247800A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202208387D0 (en) * 2022-06-08 2022-07-20 Ucl Business Ltd Modified U7 snRNA construct
WO2026080323A1 (en) 2024-10-09 2026-04-16 Quralis Corporation Treatment of neurological diseases using modulators of unc13a gene transcripts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266847A1 (en) * 1996-09-24 1998-04-02 Rapigene, Inc. Compositions and methods for enhancing hybridization specificity
US20110046200A1 (en) * 2004-08-03 2011-02-24 Michael T Howard Use of antisense oligonucleotides to effect translation modulation
EP3260540A1 (en) * 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
CA3103429A1 (en) * 2018-06-14 2019-12-19 Don W. Cleveland Compounds and methods for increasing stmn2 expression
WO2020150290A2 (en) * 2019-01-14 2020-07-23 President And Fellows Of Harvard College Methods and compositions for restoring stmn2 levels
JP7795914B2 (ja) * 2019-06-03 2026-01-08 クラリス コーポレーション 神経学的疾患を処置するためのオリゴヌクレオチドおよびその使用方法
EP4127172A4 (en) * 2020-03-25 2025-06-04 President and Fellows of Harvard College Methods and compositions for restoring STMN2 levels

Similar Documents

Publication Publication Date Title
JP2022536085A5 (https=)
JP2022517117A5 (https=)
JP2023528435A5 (https=)
BR102021018926A2 (https=)
CN306297189S (https=)
CN306298558S (https=)
CN305536302S (https=)
CN305535876S (https=)
CN305535497S (https=)
CN305533532S (https=)
CN305532333S (https=)
CN306304469S (https=)
CN305532019S (https=)
CN306301622S (https=)
CN305531363S (https=)
CN306300717S (https=)
CN306348706S (https=)
CN305531129S (https=)
CN306300495S (https=)
CN306349572S (https=)
CN306297668S (https=)
CN305529098S (https=)
CN305528199S (https=)
CN305591268S (https=)
CN306914439S (https=)